Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · Real-Time Price · USD
0.460
+0.018 (4.03%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Timothy Goodnow |
Contact Details
Address: 20451 Seneca Meadows Parkway Germantown, Maryland 20876-7005 United States | |
| Phone | 301 515 7260 |
| Website | senseonics.com |
Stock Details
| Ticker Symbol | SENS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001616543 |
| CUSIP Number | 81727U105 |
| ISIN Number | US81727U1051 |
| Employer ID | 47-1210911 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy T. Goodnow Ph.D. | President, Chief Executive Officer and Director |
| Dr. Mukul Jain Ph.D. | Chief Operating Officer |
| Kenneth L. Horton J.D. | General Counsel and Corporate Development Advisor |
| Dr. Francine Ratner Kaufman M.D. | Chief Medical Officer and Director |
| Frederick T. Sullivan CPA | Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 6, 2024 | EFFECT | Notice of Effectiveness |
| Nov 29, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 8, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 8-K | Current Report |